ATE507242T1 - Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon - Google Patents

Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon

Info

Publication number
ATE507242T1
ATE507242T1 AT06755161T AT06755161T ATE507242T1 AT E507242 T1 ATE507242 T1 AT E507242T1 AT 06755161 T AT06755161 T AT 06755161T AT 06755161 T AT06755161 T AT 06755161T AT E507242 T1 ATE507242 T1 AT E507242T1
Authority
AT
Austria
Prior art keywords
binding molecules
host cell
applications
specific binding
human binding
Prior art date
Application number
AT06755161T
Other languages
English (en)
Inventor
Mark Throsby
Kruif Cornelis De
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE507242T1 publication Critical patent/ATE507242T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06755161T 2005-05-12 2006-05-11 Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon ATE507242T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP05/52160 2005-05-12
EPPCT/EP05/52648 2005-06-08
EPPCT/EP05/52946 2005-06-23
EPPCT/EP05/54002 2005-08-15
PCT/EP2006/062250 WO2006120230A2 (en) 2005-05-12 2006-05-11 Host cell specific binding molecules capable of neutralizing viruses and uses thereof

Publications (1)

Publication Number Publication Date
ATE507242T1 true ATE507242T1 (de) 2011-05-15

Family

ID=37396920

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06755161T ATE507242T1 (de) 2005-05-12 2006-05-11 Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon

Country Status (7)

Country Link
US (2) US8052974B2 (de)
EP (1) EP1879921B1 (de)
AT (1) ATE507242T1 (de)
AU (1) AU2006245734C1 (de)
CA (1) CA2608058C (de)
IL (1) IL187321A (de)
WO (1) WO2006120230A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2314620B1 (de) 2004-05-27 2013-06-05 Crucell Holland B.V. Verfahren zur Identifikation von Bindungsmoleküle, die zur Neutralisierung des Tollwutvirus fähig sind
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP2450377A1 (de) 2006-09-07 2012-05-09 Crucell Holland B.V. Zur Neutralisierung des Influenzavirus H5N1 fähige humane Bindungsmoleküle sowie deren Verwendungen
EP2582727B8 (de) 2010-06-16 2017-04-19 University of Pittsburgh- Of the Commonwealth System of Higher Education Antikörper zu endoplasmin und deren verwendung
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CN106211773B (zh) 2014-02-11 2021-09-03 威特拉公司 用于登革病毒的抗体分子及其应用
WO2016138312A2 (en) * 2015-02-25 2016-09-01 Vanderbilt University Antibody-mediated neutralization of marburg virus
CN107847591B (zh) * 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
IL272696B2 (en) 2017-08-21 2025-01-01 Adagene Inc Dynamic human heavy chain antibody libraries
NZ761785A (en) 2017-08-21 2025-11-28 Adagene Inc Dynamic human antibody light chain libraries

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529700A (en) 1982-08-20 1985-07-16 University Of Miami Hybridoma cells secreting a monoclonal antibody specific for 5-bromo and 5-iodoeoxyuridine and reagents for measuring cellular proliferation
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
EP1018556B1 (de) 1991-09-19 2005-11-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimäre und/oder wachstumsgehemmte Flaviviren
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
HU224199B1 (hu) 1994-07-08 2005-06-28 Baxter Aktiengesellschaft Flavivírus-fertőzések elleni immunizálásra alkalmas, csupasz nukleinsavat tartalmazó vakcina
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6455509B1 (en) 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
EP0947581A4 (de) 1996-08-08 2004-07-28 Mitsubishi Pharma Corp Kulturmedium und seine verwendung.
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
EP0977587B1 (de) 1997-02-28 2005-06-15 Acambis Inc. Chimäre impfstoffe gegen flaviviren
ATE316796T1 (de) 1997-11-20 2006-02-15 Us Army Medical Res And Materi Dna impfstoffe gegen zecken-flavivieren
IL139844A0 (en) 1998-06-04 2002-02-10 Us Gov Health & Human Serv Nucleic acid vaccines for prevention of flavivirus infection
JP2002523408A (ja) 1998-08-25 2002-07-30 イェール ユニバーシティ ヘリオキサンチンおよびその類似体によるｂ型肝炎ウイルスおよびフラビウイルスの阻害および治療
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
AU774045B2 (en) 1998-09-02 2004-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Dengue viruses that are replication defective in mosquitos for use as vaccines
US6685948B1 (en) 1998-09-02 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Replication-defective dengue viruses that are replication-defective in mosquitoes for use as vaccines
HK1048138B (zh) 1999-04-15 2009-06-12 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
EP1103610A1 (de) 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
ATE526411T1 (de) 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
KR20030005197A (ko) 2000-02-18 2003-01-17 샤이어 바이오켐 인코포레이티드 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
AU2001288357A1 (en) 2000-08-23 2002-03-04 The New York Hospital Medical Center Of Queens Methods of preventing or treating west nile virus and other infections
WO2002072036A2 (en) 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
ES2257560T3 (es) 2001-06-15 2006-08-01 Crucell Holland B.V. Fagos quimericos.
HU228690B1 (en) 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
US20040009178A1 (en) 2002-02-11 2004-01-15 Bowdish Katherine S. Immunotherapeutics for biodefense
US20040258699A1 (en) 2002-02-11 2004-12-23 Bowdish Katherine S. Immunotherapeutics for biodefense
EP2287288B1 (de) 2002-07-09 2012-11-07 Baxter International Inc. Tierproteinfreies Zellkulturmedium
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
EP1601947A2 (de) 2002-10-31 2005-12-07 Health Research, Incorporated Diagnostischer test für west-nil-virus
DE60330795D1 (de) 2002-11-08 2010-02-11 Crucell Holland Bv Impfstoff gegen west nile virus
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US20070025992A1 (en) 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
WO2005063819A2 (en) 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
US7074555B2 (en) 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
WO2005111623A1 (en) 2004-05-17 2005-11-24 Crucell Holland B.V. Methods for diagnosis of acute myeloid leukemia
EP2314620B1 (de) 2004-05-27 2013-06-05 Crucell Holland B.V. Verfahren zur Identifikation von Bindungsmoleküle, die zur Neutralisierung des Tollwutvirus fähig sind
US20090130123A1 (en) 2004-06-15 2009-05-21 Erol Fikrig Antibodies to west nile virus polypeptides
US7527973B2 (en) 2004-06-21 2009-05-05 Washington University Antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
US7572456B2 (en) 2004-09-13 2009-08-11 Macrogenics, Inc. Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
JP4852046B2 (ja) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
US7498419B2 (en) 2004-10-14 2009-03-03 Washington University Crystals and structure of domain III of West Nile Virus envelope protein in association with a Fab fragment of a neutralizing antibody
US8106170B2 (en) 2004-11-11 2012-01-31 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
WO2006056006A1 (en) 2004-11-23 2006-06-01 The University Of Queensland Equine west nile virus immunotherapy
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006136601A1 (en) 2005-06-23 2006-12-28 Crucell Holland B.V. Optimization of west nile virus antibodies
CA2622603C (en) 2005-09-15 2014-06-17 Crucell Holland B.V. Method for preparing immunoglobulin libraries
MX2008014978A (es) 2006-06-06 2008-12-09 Crucell Holland Bv Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
CA2881717C (en) 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
EP2450377A1 (de) 2006-09-07 2012-05-09 Crucell Holland B.V. Zur Neutralisierung des Influenzavirus H5N1 fähige humane Bindungsmoleküle sowie deren Verwendungen

Also Published As

Publication number Publication date
US8911738B2 (en) 2014-12-16
WO2006120230A3 (en) 2007-06-21
CA2608058A1 (en) 2006-11-16
US20100303801A1 (en) 2010-12-02
US20120076794A1 (en) 2012-03-29
AU2006245734A1 (en) 2006-11-16
EP1879921A2 (de) 2008-01-23
AU2006245734C1 (en) 2012-05-24
US8052974B2 (en) 2011-11-08
IL187321A (en) 2013-06-27
WO2006120230A2 (en) 2006-11-16
IL187321A0 (en) 2008-04-13
AU2006245734B2 (en) 2011-12-01
EP1879921B1 (de) 2011-04-27
CA2608058C (en) 2013-09-10

Similar Documents

Publication Publication Date Title
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
ATE501171T1 (de) Bindungsmoleküle, die dazu fähig sind, das tollwutvirus zu neutralisieren, und anwendungen davon
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
PH12014501776A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
BRPI0510475A (pt) adenovìrus quimérico para o uso no tratamento de cáncer
CN110214154A (zh) 抗cd47抗体及其用途
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
PT1685243E (pt) Linhas celulares aviárias imortalizadas para a produção de vírus
WO2007053189A3 (en) Compositions and methods for altering immune function
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
EP2780460A4 (de) Modifizierte dna-bindende proteine und verwendungen davon
EA200801515A1 (ru) Лиганды, которые связывают il-4 и/или il-13
MX372950B (es) Anticuerpos.
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
DE602006012786D1 (de) System und Methode zur Konzentrierung und Lyse von Zellen oder Viren
DE602007008360D1 (de) Aviäre telomerase reverse transkriptase
BRPI0919236A8 (pt) Terapêutica e vacinas de combinação de gas
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
CN110177810A (zh) 抗pcsk9抗体及其用途
EP2593548A4 (de) Zusammensetzung aus dem menschlichen papillomavirus-antigen e7 und verwendungen davon
UA110918C2 (uk) Інгібітори протеїнфосфатази-1 та їх застосування
EP1937717A4 (de) Penumbra-nukleinsäuremoleküle, proteine und anwendungen davon
WO2011137441A3 (en) Sparc binding aptamers and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties